Threshold Pharmaceuticals (THLD)

Business description

Threshold is focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Ph III for STS and pancreatic cancer and earlier trials in other cancers. It is partnered with Merck KGaA.

STS Interim Analysis Preview

QuickView | Pharmaceutical & healthcare | 10/09/2014

During September the planned interim analysis of the ongoing Phase III soft tissue sarcoma (STS) trial is expected to occur. An independent committee (IDMC) will review efficacy and safety to determine next steps. Of the three possible outcomes, Threshold believes the most likely is that the trial continues as planned with overall survival data then in H215e.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.US$35.6m
Last closeUS$0.498
High / Low (52 weeks)US$1.3 / US$0.4
Stock market listingUS
Forecast net cash (US$m)31
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual26.6(1.2)(2.6)
Relative *24.2(4.6)(14.3)

* % Relative to local index

Company news